Federal Register / Vol. 86, No. 169 / Friday, September 3, 2021 / Notices 49551 

12. What are some possible challenges of 

Federal licensure? 

13. How would Federal licensure impact 

operations and other requirements, such as 

grant/contract or insurance requirements? 

14. What agency or entity should 

investigate and inspect federally licensed 

facilities? 

15. Comments regarding a Federal 

licensing scheme versus a Federal 

accreditation plan. 

16. How can considerations for an ORR 

Federal licensing, accreditation, and/or 

monitoring scheme inform additional or 

aligned guidance and standards for other fulltime child-caring facilities supported by ORR 

or HHS? 

17. What information should ORR provide 

to the public on ORR-funded or ORRlicensed shelter facilities? 

18. What resources should ORR consider if 

it develops a Federal licensing, accreditation, 

and/or monitoring program? 

19. Would a Federal licensing or 

accreditation program need to work 

differently in different care environments, 

such as residential childcare institutions, 

group homes, and child behavioral health 

facilities? 

20. Would you recommend any 

alternatives to a Federal licensing or 

accreditation scheme? 

21. Any additional topics you wish to 

provide input on. 

The information received will inform the 

planning for executing a new Federal 

licensing scheme or accreditation program. 

Dated: September 1, 2021. 

Cindy Huang, 

Director, Office of Refugee Resettlement. 

[FR Doc. 2021–19263 Filed 9–1–21; 4:15 pm] 

BILLING CODE 4184–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meetings of the Presidential Advisory 

Council on Combating AntibioticResistant Bacteria 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that two meetings are scheduled to be 

held for the Presidential Advisory 

Council on Combating AntibioticResistant Bacteria (PACCARB). The 

meetings will be open to the public via 

WebEx and teleconference; a preregistered public comment session will 

be held during both meetings. Preregistration is required for members of 

the public who wish to attend the 

meetings via WebEx/teleconference. 

Individuals who wish to send in their 

written public comment should send an 

email to CARB@hhs.gov. Registration 

information is available on the website 

http://www.hhs.gov/paccarb and must 

be completed by October 1, 2021 for the 

October 6, 2021 virtual Public Meeting; 

and, by November 29, 2021 for the 

November 30–December 1, 2021 virtual 

Public Meeting. Additional information 

about registering for the meeting and 

providing public comment can be 

obtained at http://www.hhs.gov/paccarb 

on the Upcoming Meetings page. 

DATES: The October meeting is 

scheduled to be held on October 6, 

2021, from 10:00 a.m. to 11:00 a.m. ET 

(times are tentative and subject to 

change). The November/December 

meeting is scheduled to be held on 

November 30, 2021 from 10:00 a.m. to 

3:00 p.m. and December 1, 2021, from 

10:00 a.m. to 3:00 p.m. ET (times are 

tentative and subject to change). The 

confirmed times and agenda items for 

both meetings will be posted on the 

website for the PACCARB at http://

www.hhs.gov/paccarb when this 

information becomes available. Preregistration for attending the meeting is 

strongly suggested and should be 

completed no later than October 1, 2021 

for the October meeting and November 

29, 2021 for the November/December 

meeting. 

ADDRESSES: Instructions regarding 

attending this meeting virtually will be 

posted at least one week prior to the 

meeting at: http://www.hhs.gov/ 

paccarb. 

FOR FURTHER INFORMATION CONTACT: 

Jomana Musmar, M.S., Ph.D., 

Designated Federal Officer, Presidential 

Advisory Council on Combating 

Antibiotic-Resistant Bacteria, Office of 

the Assistant Secretary for Health, U.S. 

Department of Health and Human 

Services, Room L616, Switzer Building, 

330 C St. SW, Washington, DC 20024. 

Phone: 202–746–1512; Email: CARB@

hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Presidential Advisory Council on 

Combating Antibiotic-Resistant Bacteria 

(PACCARB), established by Executive 

Order 13676, is continued by Section 

505 of Public Law 116–22, the 

Pandemic and All-Hazards 

Preparedness and Advancing Innovation 

Act of 2019 (PAHPAIA). Activities and 

duties of the Advisory Council are 

governed by the provisions of the 

Federal Advisory Committee Act 

(FACA), Public Law 92–463, as 

amended (5 U.S.C. app.), which sets 

forth standards for the formation and 

use of federal advisory committees. 

The PACCARB shall advise and 

provide information and 

recommendations to the Secretary 

regarding programs and policies 

intended to reduce or combat antibioticresistant bacteria that may present a 

public health threat and improve 

capabilities to prevent, diagnose, 

mitigate, or treat such resistance. The 

PACCARB shall function solely for 

advisory purposes. 

Such advice, information, and 

recommendations may be related to 

improving: The effectiveness of 

antibiotics; research and advanced 

research on, and the development of, 

improved and innovative methods for 

combating or reducing antibiotic 

resistance, including new treatments, 

rapid point-of-care diagnostics, 

alternatives to antibiotics, including 

alternatives to animal antibiotics, and 

antimicrobial stewardship activities; 

surveillance of antibiotic-resistant 

bacterial infections, including publicly 

available and up-to-date information on 

resistance to antibiotics; education for 

health care providers and the public 

with respect to up-to-date information 

on antibiotic resistance and ways to 

reduce or combat such resistance to 

antibiotics related to humans and 

animals; methods to prevent or reduce 

the transmission of antibiotic-resistant 

bacterial infections; including 

stewardship programs; and coordination 

with respect to international efforts in 

order to inform and advance the United 

States capabilities to combat antibiotic 

resistance. 

The October 6, 2021 public meeting 

will be held virtually and is dedicated 

to deliberation and vote of the letter 

with recommendations from the 

Immediate Action Subcommittee of the 

Advisory Council. The meeting agenda 

will be posted on the PACCARB website 

at http://www.hhs.gov/paccarb when it 

has been finalized. All agenda items are 

tentative and subject to change. 

The November 31, 2021 and 

December 1, 2021 public meeting will 

be held virtually and will be dedicated 

to addressing the current situation 

regarding antimicrobial resistance as 

well as to a presentation from the 

National Academies of Sciences, 

Engineering, and Medicine on their 

report, Examining the Long-term Health 

and Economic Effects of Antimicrobial 

Resistance in the United States. The 

meeting agenda will be posted on the 

PACCARB website at http://

www.hhs.gov/paccarb when it has been 

finalized. All agenda items are tentative 

and subject to change. 

Instructions regarding attending both 

meetings virtually will be posted one 


lotter on DSK11XQN23PROD with NOTICES1
49552 Federal Register / Vol. 86, No. 169 / Friday, September 3, 2021 / Notices 

week prior to each meeting at: http://

www.hhs.gov/paccarb. 

Members of the public will have the 

opportunity to provide comments live 

during the October meeting via 

conference line by pre-registering online 

at http://www.hhs.gov/paccarb. Preregistration is required for participation 

in this session with limited spots 

available. Written public comments can 

also be emailed to CARB@hhs.gov by 

midnight October 1, 2021 and should be 

limited to no more than one page. All 

public comments received prior to 

October 1, 2021, will be provided to 

Advisory Council members. 

Members of the public will have the 

opportunity to provide comments live 

during the November 30, 2021 and 

December 1, 2021 public meeting via 

conference line by pre-registering online 

at http://www.hhs.gov/paccarb. There 

will be two separate sessions available 

for public comment: An Innovation 

Spotlight will be held on November 30, 

2021 where companies and/or 

organizations involved in combating 

antibiotic resistance have an 

opportunity to present their work to 

members of the Advisory Council; and 

on December 1, 2021, where all 

members of the general public are 

welcome to provide oral comment 

during this separate session. Preregistration is required for participation 

in these sessions with limited spots 

available. Further information about 

these two sessions can be found online 

at http://www.hhs.gov/paccarb. Written 

public comments can also be emailed to 

CARB@hhs.gov by midnight November 

29, 2021 and should be limited to no 

more than one page. All public 

comments received prior to November 

29, 2021, will be provided to Advisory 

Council members. 

Dated: August 26, 2021. 

Jomana F. Musmar, 

Designated Federal Officer, Presidential 

Advisory Council on Combating AntibioticResistant Bacteria, Office of the Assistant 

Secretary for Health. 

[FR Doc. 2021–19027 Filed 9–2–21; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: September 27–28, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E70A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Soheyla Saadi, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E70A, Rockville, MD 

20852, (240) 669–5178, saadisoh@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 31, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19110 Filed 9–2–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health: 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Clinical Trials to Test the Effectiveness of 

Treatment, Preventive, and Services 

Interventions (R01, Collaborative R01, R34). 

Date: October 1, 2021. 

Time: 9:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Marcy Ellen Burstein, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6143, MSC 9606, 

Bethesda, MD 20892–9606, 301–443–9699, 

bursteinme@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; Early 

Phase Trials of Pharmacological and Device 

Based Interventions. 

Date: October 5, 2021. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Nicholas Gaiano, Ph.D., 

Review Branch Chief, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center/Room 

6150/MSC 9606, 6001 Executive Boulevard, 

Bethesda, MD 20892–9606, 301–443–2742, 

nick.gaiano@nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; Pilot 

Effectiveness Trials of Interventions for 

Preschoolers with ADHD (R34). 

Date: October 5, 2021. 

Time: 12:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Rebecca Steiner Garcia, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6149, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–4525, 

steinerr@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; NonPharmacological Clinical Trials. 

Date: October 8, 2021. 

Time: 9:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Nicholas Gaiano, Ph.D., 

Review Branch Chief, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center/Room 


lotter on DSK11XQN23PROD with NOTICES1